AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10486683 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measurement (SM) of blood pressure using an Omron device for 5 consecutive days (3 measures morning and night)
Number of subjects: 32
Study 10486683 — intervention group
Group type: COMPARATOR
Intervention: Office measurements (OM) of blood pressure using a mercury sphygmomanometer (4 measures)
Number of subjects: 32
Study 8759665 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacteol Fort
Number of subjects: 18
Study 8759665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1810356 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release metoclopramide 15 mg (Gastrobid Continus tablets) given twice daily
Number of subjects: 95
Study 1810356 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg given three times daily
Number of subjects: 95
Study 1810356 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg given three times daily
Number of subjects: 95
Study 1810356 — intervention group
Group type: COMPARATOR
Intervention: Controlled release metoclopramide and domperidone (both doses)
Number of subjects: 95
Study 6636262 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized plasma at 4.0 ng/ml
Number of subjects: 0
Study 6636262 — intervention group
Group type: COMPARATOR
Intervention: Serum at 4.0 ng/ml
Number of subjects: 0
Study 6636262 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preparation procedures
Number of subjects: 0
Study 31707814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 158
Study 31707814 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 158
Study 31707814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 31238021 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information
Number of subjects: 66
Study 31238021 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information
Number of subjects: 66
Study 31238021 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous surgical experience
Number of subjects: 66
Study 31238021 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 66
Study 28510741 — intervention group
Group type: EXPERIMENTAL
Intervention: Early FFP administration (FFP in the CPB priming solution)
Number of subjects: 73
Study 28510741 — intervention group
Group type: COMPARATOR
Intervention: Late FFP administration (FFP given immediately after CPB)
Number of subjects: 73
Study 26036209 — intervention group
Group type: EXPERIMENTAL
Intervention: Huber group (feedback-based balance and core resistance training)
Number of subjects: 34
Study 26036209 — intervention group
Group type: COMPARATOR
Intervention: Pilates group (conventional Pilates training)
Number of subjects: 34
Study 23444177 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel
Number of subjects: 21
Study 23444177 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide/camphorated paramonochlorophenol (Callen PMCC)
Number of subjects: 21
Study 23444177 — intervention group
Group type: COMPARATOR
Intervention: One-visit endodontic treatment
Number of subjects: 21
Study 23444177 — intervention group
Group type: EXPERIMENTAL
Intervention: Callen PMCC
Number of subjects: 21
Study 21185738 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mixed tocopherols 666 IU/day and alpha lipoic acid (ALA) 600 mg/day for 8 weeks
Number of subjects: 62
Study 21185738 — intervention group
Group type: COMPARATOR
Intervention: Matching placebos for 8 weeks
Number of subjects: 62
Study 18803070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 80‐160 mg/day (n=147)
Number of subjects: 293
Study 18803070 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine 10‐20 mg/day (n=24)
Number of subjects: 293
Study 18803070 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 4‐8 mg/day (n=22)
Number of subjects: 293
Study 18803070 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine 300‐750 mg/day (n=97)
Number of subjects: 293
Study 17196274 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation (Heart Manual) for 6 weeks
Number of subjects: 230
Study 17196274 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based rehabilitation for 8-10 weeks
Number of subjects: 230
Study 17196274 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation (Heart Manual)
Number of subjects: 230
Study 17196274 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based rehabilitation
Number of subjects: 230
Study 15554404 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumoral muscle exercises
Number of subjects: 0
Study 12478024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumovax vaccination at 14 days post-splenectomy
Number of subjects: 40
Study 12478024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumovax vaccination at 28 days post-splenectomy
Number of subjects: 40
Study 12478024 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy adults (control group)
Number of subjects: 40
Study 9825977 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 40 mg/kg/d, intravenously or orally
Number of subjects: 155
Study 9825977 — intervention group
Group type: COMPARATOR
Intervention: Not treated (Control)
Number of subjects: 155
Study 9825977 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 155
Study 7651074 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil diet (MUFA)
Number of subjects: 59
Study 7651074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil diet (PUFA)
Number of subjects: 59
Study 7651074 — intervention group
Group type: COMPARATOR
Intervention: Both diets (MUFA and PUFA)
Number of subjects: 59
Study 2668325 — intervention group
Group type: EXPERIMENTAL
Intervention: sc injections of SMS 201‐995 every 2 hours (q2h)
Number of subjects: 10
Study 2668325 — intervention group
Group type: COMPARATOR
Intervention: sc injections of SMS 201‐995 every 8 hours (q8h)
Number of subjects: 10
Study 1245160 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate preparation 1
Number of subjects: 64
Study 1245160 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate preparation 2
Number of subjects: 64
Study 1245160 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-pyridylcarbinol
Number of subjects: 64
Study 6783523 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically defined diet (CDD)
Number of subjects: 20
Study 6783523 — intervention group
Group type: COMPARATOR
Intervention: Water ‐ electrolyte substitution via peripheral veins
Number of subjects: 20
Study 31525257 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocaine spray (8 puffs of 10% Lidocaine, 80 mg)
Number of subjects: 570
Study 31525257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 puffs of sterile normal saline)
Number of subjects: 570
Study 31525257 — intervention group
Group type: COMPARATOR
Intervention: Control (no spray)
Number of subjects: 570
Study 29527345 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health workers (LHW) supporting nurses in chronic disease care for 18 months
Number of subjects: 0
Study 29527345 — intervention group
Group type: COMPARATOR
Intervention: Control clinics with usual care
Number of subjects: 0
Study 26799692 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg once daily + Sofosbuvir 400 mg once daily for 12 weeks
Number of subjects: 310
Study 26799692 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg once daily + Sofosbuvir 400 mg once daily for 8 weeks
Number of subjects: 310
Study 24117232 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive moderate dose lithium therapy
Number of subjects: 283
Study 24117232 — intervention group
Group type: COMPARATOR
Intervention: Optimized treatment
Number of subjects: 283
Study 22530944 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR 30.0-59.9 mL/min/1.73 m²
Number of subjects: 5555
Study 22530944 — intervention group
Group type: COMPARATOR
Intervention: eGFR ≥ 90.0 mL/min/1.73 m²
Number of subjects: 5555
Study 20224449 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Shuttle Sprint (RS) training
Number of subjects: 15
Study 20224449 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive Strength (ExpS) training
Number of subjects: 15
Study 20224449 — intervention group
Group type: COMPARATOR
Intervention: Both RS and ExpS
Number of subjects: 15
Study 16926184 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with sulfasalazine and methotrexate (MTX)
Number of subjects: 687
Study 16926184 — intervention group
Group type: COMPARATOR
Intervention: SASP alone
Number of subjects: 687
Study 16926184 — intervention group
Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 687
Study 16926184 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 687
Study 12760727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasphincteric injections of botulinum toxin (group 1: 10 patients)
Number of subjects: 22
Study 12760727 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections of 1% polidocanol (group 2: 6 patients)
Number of subjects: 22
Study 12760727 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with botulinum toxin and polidocanol (group 3: 6 patients)
Number of subjects: 22
Study 10995590 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper arm occlusion
Number of subjects: 28
Study 10995590 — intervention group
Group type: COMPARATOR
Intervention: Forearm occlusion
Number of subjects: 28
Study 9357940 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected children with advanced disease
Number of subjects: 35
Study 9357940 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected patients responding to antiretroviral therapy
Number of subjects: 35
Study 9357940 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 35
Study 8453557 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional RT plus six cycles of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 44
Study 8453557 — intervention group
Group type: COMPARATOR
Intervention: Regional RT alone
Number of subjects: 44
Study 8453557 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional RT plus six cycles of CHOP chemotherapy
Number of subjects: 44
Study 3769386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 160 mg/day
Number of subjects: 7
Study 3769386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 240 mg/day
Number of subjects: 7
Study 3769386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 320 mg/day
Number of subjects: 7
Study 3769386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol (all doses)
Number of subjects: 7
Study 3769386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 27920153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study 27920153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26543645 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, 1 µg/kg (group D)
Number of subjects: 54
Study 26543645 — intervention group
Group type: COMPARATOR
Intervention: Midazolam, 0.02 mg/kg (group M)
Number of subjects: 54
Study 23725006 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Volume Training (HVT)
Number of subjects: 20
Study 23725006 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 20
Study 22080997 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (20 Hz, 10 second trains, intensity 80% of motor threshold) for 10 minutes daily for five consecutive days
Number of subjects: 27
Study 22080997 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 27
Study 22080997 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 27
Study 19898644 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan +/- HCTZ
Number of subjects: 1285
Study 19898644 — intervention group
Group type: COMPARATOR
Intervention: amlodipine +/- HCTZ
Number of subjects: 1285
Study 19898644 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 1285
Study 17523002 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product 1 (estradiol and levonorgestrel)
Number of subjects: 2
Study 17523002 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product 2 (estradiol and levonorgestrel)
Number of subjects: 2
Study 17523002 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product 3 (estradiol and levonorgestrel)
Number of subjects: 2
Study 15471384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 83
Study 11456360 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 1000 mg three times daily for 7 days
Number of subjects: 57
Study 11456360 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir 800 mg five times daily for 7 days
Number of subjects: 57
Study 9623637 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T4 replacement treatment in hypothyroid patients
Number of subjects: 35
Study 9623637 — intervention group
Group type: EXPERIMENTAL
Intervention: Restoration of euthyroidism in hyperthyroid patients
Number of subjects: 35
Study 8186168 — intervention group
Group type: EXPERIMENTAL
Intervention: Question prompt sheet
Number of subjects: 142
Study 8186168 — intervention group
Group type: COMPARATOR
Intervention: General information sheet
Number of subjects: 142
Study 3308052 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 30
Study 3308052 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 30
Study 3308052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29064128 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent haemodialysis (6×/week)
Number of subjects: 195
Study 29064128 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemodialysis (3×/week)
Number of subjects: 195
Study 29064128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal haemodialysis
Number of subjects: 195
Study 28422591 — intervention group
Group type: EXPERIMENTAL
Intervention: Papacarie
Number of subjects: 50
Study 28422591 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic Restorative Treatment (ART)
Number of subjects: 50
Study 25264024 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (4 mg/kg median)
Number of subjects: 25
Study 25264024 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 25
Study 25264024 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 25
Study 23553259 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL of 4% lidocaine (anesthetized condition)
Number of subjects: 20
Study 23553259 — intervention group
Group type: COMPARATOR
Intervention: Nonanesthetized condition (control)
Number of subjects: 20
Study 21615734 — intervention group
Group type: EXPERIMENTAL
Intervention: PSSA intervention
Number of subjects: 203
Study 21615734 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 203
Study 19755925 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 (P500)
Number of subjects: 216
Study 19755925 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 1000 mg/m2 (P1000)
Number of subjects: 216
Study 19755925 — intervention group
Group type: COMPARATOR
Intervention: Control group (squamous histology)
Number of subjects: 216
Study 17092968 — intervention group
Group type: EXPERIMENTAL
Intervention: TPA023 0.5 mg
Number of subjects: 12
Study 17092968 — intervention group
Group type: EXPERIMENTAL
Intervention: TPA023 1.5 mg
Number of subjects: 12
Study 17092968 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 12
Study 17092968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15117045 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg celecoxib
Number of subjects: 110
Study 15117045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 11261347 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft hydrogel contact lenses worn daily for 12 months
Number of subjects: 80
Study 11261347 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic control subjects
Number of subjects: 80
Study 9853164 — intervention group
Group type: EXPERIMENTAL
Intervention: Enclosed thrombolysis (ET) and percutaneous transluminal angioplasty (PTA)
Number of subjects: 25
Study 9853164 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA) alone
Number of subjects: 25
Study 9853164 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ET/PTA and PTA)
Number of subjects: 25
Study 7989433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nested polymerase chain reaction (PCR)
Number of subjects: 23
Study 7989433 — intervention group
Group type: COMPARATOR
Intervention: Single round polymerase chain reaction followed by Southern blot hybridization
Number of subjects: 23
Study 7989433 — intervention group
Group type: COMPARATOR
Intervention: Virus isolation
Number of subjects: 23
Study 2543280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal alpha 2b interferon (IFN) 5 x 10(6) IU on day 1 and 2.5 x 10(6) IU on each subsequent day for 5 days
Number of subjects: 199
Study 2543280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 31885339 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral holmium laser resection (THOLR)
Number of subjects: 218
Study 31885339 — intervention group
Group type: COMPARATOR
Intervention: Transurethral electrocision (TUR)
Number of subjects: 218
Study 31885339 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral holmium laser resection (THOLR) and Transurethral electrocision (TUR) with intravesical epirubicin
Number of subjects: 218
Study 29742712 — intervention group
Group type: EXPERIMENTAL
Intervention: WORD DPP (faith-based Diabetes Prevention Program)
Number of subjects: 384
Study 29742712 — intervention group
Group type: COMPARATOR
Intervention: PILI DPP (Pacific culturally adapted Diabetes Prevention Program)
Number of subjects: 384
Study 29115949 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 20
Study 29115949 — intervention group
Group type: COMPARATOR
Intervention: PSV
Number of subjects: 20
Study 25727913 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-handed surgical ties (28 students)
Number of subjects: 58
Study 25727913 — intervention group
Group type: COMPARATOR
Intervention: 2-handed surgical ties (30 students)
Number of subjects: 58
Study 23485660 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal manual treatment approach (joint mobilization, neural mobilization, and exercise)
Number of subjects: 60
Study 23485660 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (sham)
Number of subjects: 60
Study 23485660 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal manual treatment approach
Number of subjects: 60
Study 22085439 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 mug bid
Number of subjects: 613
Study 22085439 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 9 mug bid
Number of subjects: 613
Study 22085439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study 19662914 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric IOLs (Acrysof SN60WF or Tecnis Z9000)
Number of subjects: 100
Study 19662914 — intervention group
Group type: COMPARATOR
Intervention: Spherical IOLs (Acrysof SN60AT or Sensar AR40e)
Number of subjects: 100
Study 19662914 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric IOLs
Number of subjects: 100
Study 17205144 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (Diovan) 80 mg/day for 7 days
Number of subjects: 80
Study 17205144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15132875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 5 mg three times daily for 4 weeks
Number of subjects: 231
Study 15132875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 231
Study 15132875 — intervention group
Group type: COMPARATOR
Intervention: Domperidone 10 mg three times daily for 4 weeks
Number of subjects: 231
Study 11402745 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for two weeks
Number of subjects: 60
Study 11402745 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily for ten days
Number of subjects: 60
Study 9143861 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg to 50 mg daily after 6 weeks)
Number of subjects: 56
Study 9143861 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 56
Study 1826192 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF infusion at 1 pmol/kg/min
Number of subjects: 8
Study 1826192 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF infusion at 3 pmol/kg/min
Number of subjects: 8
Study 1826192 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF infusion at 10 pmol/kg/min
Number of subjects: 8
Study 1826192 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 8
Study 7057318 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose elimination diet
Number of subjects: 40
Study 7057318 — intervention group
Group type: COMPARATOR
Intervention: Lactose ingestion (2 gm/kg of body weight; maximum 50 gm)
Number of subjects: 40
Study 30288602 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity programme of 150 min moderate walking per week
Number of subjects: 44
Study 30288602 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 44
Study 29064929 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated preterm formula at 30 kcal/oz (CPF30)
Number of subjects: 0
Study 29064929 — intervention group
Group type: COMPARATOR
Intervention: Conventional powdered human milk fortifier (PHMF)
Number of subjects: 0
Study 26084590 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept continuous regimen (50 mg/week)
Number of subjects: 54
Study 26084590 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept intermittent regimen
Number of subjects: 54
Study 26084590 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (overall)
Number of subjects: 54